SGD Pharma, the leading global provider of molded glass primary packaging solutions for the pharmaceutical industry, has announced the inauguration of a new siliconization facility at its advanced Saint-Quentin Lamotte (SQLM) plant.
This move further enriches the company's comprehensive suite of in-house services by bringing its glass siliconization process in-house, thereby enhancing responsiveness, ensuring a secure supply chain, and offering greater flexibility in vial sizes. While glass vials are commonly employed in pharmaceutical packaging, there is a growing demand for primary packaging solutions tailored to handle more sensitive, aggressive, and viscous drug formulations.
The application of a micro-layer silicone-based internal coating to the vial offers a protective barrier that reduces interaction between the drug product and the primary packaging, while maintaining the integrity of delicate therapeutic formulations.
SGD Pharma employs an optimized spraying technique to ensure uniform coverage of the vial surface, resulting in enhanced performance of the internal silicone layer. This process is meticulously executed under stringent quality control measures within an ISO 8 clean room environment, operating in an ISO 15378 certified facility.
The new siliconization facility at SQLM accommodates all types of glass and vial sizes ranging from 3ml to 500ml, available in both clear and amber glass, with high processing capabilities. This treatment option caters to a diverse array of market segments including anti-infectives, parenteral nutrition, diagnostics, animal health, and oncology, among others.
